The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy

NCT00005918 Phase 3 COMPLETED

The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).

Details

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 3
Status	COMPLETED
Enrolment	730
Start date	2000-06
Completion	2002-04

Conditions

• HIV Infections

Interventions

• Efavirenz
• Lamivudine
• Stavudine

Countries

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Israel, Italy, Mexico, Portugal, Puerto Rico, Russia, South Africa, Spain, Thailand